Sugi Predict

Sugi Predict / Compounds / SCHEMBL4404451

SCHEMBL4404451

SCHEMBL4404451

COC(=O)c1c(F)c(F)c(NCc2ccccc2)c(F)c1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ CA2 P00918 3/20 0.54
▸ CA1 P00915 2/20 0.54
▸ CA13 Q8N1Q1 2/20 0.52
▸ CA12 O43570 1/20 0.52
▸ CA7 P43166 1/20 0.52
▸ ALOX5 P09917 1/20 0.52
▸ CASP3 P42574 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ MAPT P10636 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ CRHBP P24387 1/20 0.41
▸ CRHR2 Q13324 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4406810 0.87 CA1 (0.50) TSHRMAPK1CA2CA1CA13
SCHEMBL19478138 0.87 CA2 (0.50) TSHRMAPK1CA2CA1CA13
SCHEMBL15470920 0.84 CA2 (0.55) TSHRMAPK1CA2CA1CA13
SCHEMBL21371036 0.84 CA2 (0.58) TSHRCA2CA1CA13CA12
SCHEMBL19478209 0.84 CA2 (0.47) TSHRMAPK1CA2CA1CA13
SCHEMBL4405351 0.79 CYP2C9 (0.49) TSHRCA2CA1CA13CA12
SCHEMBL29950022 0.78 CA2 (0.66) TSHRCA2CA1CA13CA12
SCHEMBL26507127 0.77 CA1 (0.49) TSHRCA2CA1ALOX5CASP3
SCHEMBL31644614 0.76 LMNA (0.58) TSHRALDH1A1KDM4EGAAMAPT
SCHEMBL6644943 0.75 ALDH1A1 (0.47) CA2CA1CA13CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112867716-A Solid forms of FGFR inhibitors and methods for their preparation 因赛特公司 2021-05-28 — — CN claimed
EP-3788047-A2 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME Incyte Corporation (US) 2021-03-10 — — EP claimed
US-20190337948-A1 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME WILMINGTON PHARMATECH 2019-11-07 — — US claimed
US-12552792-B2 Solid forms of an FGFR inhibitor and processes for preparing the same INCYTE CORPORATION (US) 2026-02-17 — — US disclosed
US-20250276970-A1 DERIVATIVES OF AN FGFR INHIBITOR INCYTE CORPORATION 2025-09-04 — — US disclosed
CN-119241542-A Solid forms of FGFR inhibitors and methods of making the same 因赛特公司 2025-01-03 — — CN disclosed
CN-119241540-A Solid forms of FGFR inhibitors and methods of making the same 因赛特公司 2025-01-03 — — CN disclosed
CN-119241541-A Solid forms of FGFR inhibitors and methods of making the same 因赛特公司 2025-01-03 — — CN disclosed
US-20240425506-A1 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME INCYTE CORPORATION 2024-12-26 — — US disclosed
US-12168660-B2 Derivatives of an FGFR inhibitor INCYTE CORPORATION (US) 2024-12-17 — — US disclosed
CN-112867716-B Solid forms of FGFR inhibitors and methods of making the same 因赛特公司 2024-09-13 — — CN disclosed
US-20140171405-A1 Fused Pyrazoles as FGFR Inhibitors INCYTE CORPORATION (US) 2014-06-19 — — US disclosed
US-20140045814-A1 PYRAZINE DERIVATIVES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2014-02-13 — — US disclosed
WO-2014007951-A2 SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS INCYTE CORPORATION (US) 2014-01-09 — — WO disclosed
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 — — EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 — — US disclosed
WO-2006038112-A1 USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS WARNER-LAMBERT COMPANY LLC (US) 2006-04-13 — — WO disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 — — EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 — — WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171405-A1 Fused Pyrazoles as FGFR Inhibitors FGFR1, FGFR3, FGFR2 TSHR 2517/4885MAPK1 1811/4885CA2 3612/4885
US-20190337948-A1 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME FGFR1, FGFR2, FGFR3 TSHR 2037/4885MAPK1 764/4885CA2 4250/4885
US-12168660-B2 Derivatives of an FGFR inhibitor FGFR1, FGFR2, FGFR4 TSHR 1177/4885MAPK1 1209/4885CA2 3457/4885
US-20240425506-A1 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME FGFR1, FGFR2, FGFR3 TSHR 2037/4885MAPK1 764/4885CA2 4250/4885
US-20250276970-A1 DERIVATIVES OF AN FGFR INHIBITOR FGFR1, FGFR2, FGFR4 TSHR 1177/4885MAPK1 1209/4885CA2 3457/4885
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 TSHR 3028/4885MAPK1 91/4885CA2 3890/4885
US-12552792-B2 Solid forms of an FGFR inhibitor and processes for preparing the same FGFR2, FGFR1, FGF2 TSHR 919/4885MAPK1 903/4885CA2 2874/4885
US-20140045814-A1 PYRAZINE DERIVATIVES AS FGFR INHIBITORS FGFR1, FGFR2, FGFR3 TSHR 2233/4885MAPK1 1438/4885CA2 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.